Introduction
============

Chronic kidney disease (CKD) is a major global problem caused by the permanent loss of kidney function, and is also associated with an increased risk for cardiovascular disease ([@B9]; [@B45]; [@B7]; [@B50]; [@B48]; [@B22]; [@B39]; [@B51]). The overall prevalence of CKD exceeds 10%, and is approximately 14% in the general population and its incidence is increasing ([@B2]; [@B21]; [@B42]; [@B63]; [@B16]; [@B22]; [@B8]). It is reported that up to 20% of CKD cases are caused by genetic forms of renal disease ([@B2]; [@B21]; [@B42]; [@B63]; [@B16]; [@B22]; [@B8]). Understanding genetic predisposition to CKD and uncovering underlying pathophysiological mechanisms may contribute to the development of targeted therapies. In recent years, the genetic predisposition to CKD has been widely evaluated especially using the genome-wide association studies (GWAS), which highlighted some novel genetic susceptibility variants in many genes, and estimated glomerular filtration rate to diagnose and stage CKD ([@B44]; [@B63]).

In these CKD risk genes, a genetic variant rs7805747 in PRKAG2 was identified to be significantly associated with both serum creatinine and CKD with genome wide significance level ([@B7]). The rs7805747 (chr7:151407801 for hg19) variant is located in intronic of PRKAG2. PRKAG2 is a protein coding gene. Until now, the potential mechanism by which rs7805747 affects CKD risk is still unclear. It is difficult to identify the function of coding and non-coding genes in molecular wet laboratories. However, computational methods including kinds of bioinformatics software and databases may be useful tools to guide and predict function ([@B68]; [@B58]; [@B57]; [@B61],[@B62]; [@B14],[@B15]; [@B23],[@B24]; [@B25]; [@B65]). Here, we performed a functional analysis of rs7805747 variant using multiple bioinformatics databases including RegulomeDB ([@B4]), HaploReg (version 4.1) ([@B60]), PhenoScanner (version 1.1) ([@B53]), and UCSC Genome Browser ([@B47]; [@B55]; [@B6]), as did in previous studies ([@B38]; [@B46]; [@B13]; [@B35], [@B30],[@B31],[@B32],[@B33],[@B34], [@B37]; [@B12]; [@B19],[@B20]; [@B26]; [@B67]). Meanwhile, we analyzed a whole genome case-control expression profiles in human CKD to investigate whether the susceptibility gene PRKAG2 is differently expressed in CKD cases compared with control samples.

Materials and Methods {#s1}
=====================

Regulatory Analysis of rs7805747 Using RegulomeDB
-------------------------------------------------

RegulomeDB database could annotate genetic variants with known and predicted regulatory elements in the intergenic regions of the human genome ([@B4]). In brief, the known and predicted regulatory DNA elements include regions of DNAase hypersensitivity, binding sites of transcription factors, and promoter regions that have been biochemically characterized to regulation transcription ([@B4]). These regulatory element datasets are from Gene Expression Omnibus (GEO), the Encyclopedia of DNA Elements (ENCODE) project, and published literature ([@B4]).

Functional Analysis of rs7805747 Using HaploReg
-----------------------------------------------

HaploReg is a tool for exploring annotations of the non-coding variants ([@B59], [@B60]). HaploReg v4 included LD information from the 1000 Genomes Project, chromatin state and protein binding annotation from the Roadmap Epigenomics and ENCODE projects, sequence conservation across mammals, the effect of SNPs on regulatory motifs, and the effect of SNPs on expression from eQTL studies ([@B59], [@B60]). More detailed information is provided in the original studies ([@B59], [@B60]).

Functional Analysis of rs7805747 Using PhenoScanner
---------------------------------------------------

PhenoScanner included publicly available large-scale GWAS summary results, about 3 billion associations and over 10 million unique single nucleotide polymorphisms (SNPs) and a broad range of phenotypes ([@B53]). The results are aligned across traits to the same effect and non-effect alleles for each SNP ([@B53]). Here, we performed three kinds of functional analyses including the GWAS, Metabolites, and eQTL analysis options ([@B53]). To perform a GWAS analysis, the PhenoScanner included 88 GWAS datasets with 76 kinds of diseases or phenotypes ([@B53]). To perform a Metabolites analysis, PhenoScanner consisted of two metabolomics datasets ([@B49]; [@B28]). To perform an eQTL analysis, PhenoScanner included several eQTL datasets from eQTL Browser, Geuvadis, GTEx (version 6), MuTHER and bloodeqtlbrowser. More detailed information is provided on the original study ([@B53]).

Gene Expression Analysis of PRKAG2 in GTEx
------------------------------------------

We evaluated the expression of PRKAG2 using the RNA-Seq datasets from the NIH Genotype-Tissue Expression (GTEx) project, which was created to establish a sample and data resource for studies on the relationship between genetic variation and gene expression in multiple human tissues ([@B11]; [@B40]). The GTEx project included median gene expression levels in 51 tissues and 2 cell lines (V6, October 2015) ([@B11]; [@B40]). This release is based on data from 8555 tissue samples obtained from 570 adult post-mortem individuals ([@B11]; [@B5]; [@B40]). Here, we used the Genome Browser to evaluate the expression of PRKAG2 in GTEx 53 human tissues (V6, October 2015). The UCSC Genome Browser is a new method to visualize interactions between regions of the genome ([@B41]; [@B27]; [@B47]; [@B52]; [@B55]; [@B6]).

Case-Control Gene Expression Analysis of PRKAG2
-----------------------------------------------

We analyzed a whole genome case-control expression profiles in human CKD ([@B43]). In the original study, a microarray analysis with renal biopsy specimens from CKD patients was conducted to identify the responsible genes associated with tubulointerstitial fibrosis and tubular cell injury in CKD ([@B43]). This study showed microarray profiles in a total of 61 samples including 53 biopsy specimens of CKD patients, and 8 controls ([@B43]). Here, we selected the web tool GEO2R to evaluate whether PRKAG2 gene is significantly dysregulated in CKD cases compared with control samples, as did in a recent study ([@B36]). The significance level is defined to be *P* \< 0.01.

Results
=======

Regulatory Analysis of rs7805747 Using RegulomeDB
-------------------------------------------------

Using RegulomeDB, the predicted score is 5, which suggested that rs7805747 is likely to affect binding (TF binding) or DNase peak. The predicted binding protein is HNF4A (chr7:151407767-151408030 by ChIP-seq in Caco2 cell type) ([@B56]). The histone modification analysis showed that rs7805747 was predicated to locate in enhancer histone marks (Liver, Fetal Intestine Large, Right Ventricle, Duodenum Mucosa, and Fetal Intestine Small). Here, we provided some key information about regulatory analysis in Table [1](#T1){ref-type="table"}. More detailed results are described in Supplementary Table [1](#SM1){ref-type="supplementary-material"}.

###### 

Key histone modification analysis of rs7805747 using RegulomeDB.

  Method     Location                    Chromatin state        Tissue
  ---------- --------------------------- ---------------------- ------------------------------------------
  ChromHMM   chr7:151407000..151408400   Enhancers              Fetal intestine large
  ChromHMM   chr7:151407200..151408000   Enhancers              Right ventricle
  ChromHMM   chr7:151407200..151408200   Enhancers              Duodenum mucosa
  ChromHMM   chr7:151407400..151411400   Enhancers              Liver
  ChromHMM   chr7:151407000..151408600   Genetic enhancers      Fetal intestine small
  ChromHMM   chr7:151406000..151408400   Heterochromatin        H9 derived neuron cultured cells
  ChromHMM   chr7:151407400..151408400   Repressed PolyComb     Foreskin fibroblast primary cells skin01
  ChromHMM   chr7:151407800..151408400   Repressed PolyComb     Foreskin fibroblast primary cells skin02
  ChromHMM   chr7:151405400..151410400   Strong transcription   Monocytes-CD14+ RO01746 primary cells
  ChromHMM   chr7:151405600..151408000   Strong transcription   Primary monocytes from peripheral blood
                                                                

Functional Analysis of rs7805747 Using HaploReg
-----------------------------------------------

Using HaploReg v4, rs7805747 is predicated to locate in enhancer histone marks (Liver, Duodenum Mucosa, Fetal Intestine Large, Fetal Intestine Small, and Right Ventricle tissues), DNase hypersensitivity (Foreskin Melanocyte Primary Cells skin01, Fetal Heart, Fetal Intestine Large, Fetal Intestine Small, Small Intestine), and motifs changed (GATA, HMGN3, Pax-6, and Tgif1) ([@B59], [@B60]).

Functional Analysis of rs7805747 Using PhenoScanner in GWAS
-----------------------------------------------------------

Using PhenoScanner in GWAS option, we identified 43 significant association results with *P* \< 0.01. In addition to the CKD, we found that rs7805747 is also significantly associated with other diseases or phenotypes including Hemoglobin Hb, Hematocrit Hct, Red blood cell count RBC, systolic blood pressure (SBP), Breast cancer, Gout, Hypertension, and Extraversion, as described in Table [2](#T2){ref-type="table"}.

###### 

Significant association between rs7805747 and kinds of diseases or phenotypes with *P* ≤ 0.01.

  SNP         Trait                                                                             PMID       *P*-value   Samples
  ----------- --------------------------------------------------------------------------------- ---------- ----------- ---------
  rs7805747   log(eGFR creatinine in non-diabetics)                                             26831199   1.50E-29    116602
  rs7805747   log(eGFR creatinine)                                                              26831199   8.00E-29    131772
  rs7805747   Chronic kidney disease                                                            26831199   2.10E-14    117165
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR without diabetes       22479191   4.00E-14    130600
  rs7805747   Serum creatinine                                                                  20383146   2.00E-13    90075
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR                        22479191   2.70E-13    130600
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR no diabetes            20383146   9.20E-13    90075
  rs7805747   Chronic kidney disease                                                            20383146   4.00E-12    NA
  rs7805747   Kidney diseases                                                                   20383146   4.00E-12    NA
  rs7805747   Chronic kidney disease                                                            20383146   4.20E-12    90075
  rs7805747   log(eGFR creatinine)                                                              20383146   5.10E-11    67093
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR                        20383146   5.10E-11    90075
  rs7805747   Chronic kidney disease                                                            22479191   6.00E-10    130600
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR age 65                 22479191   7.10E-10    130600
  rs7805747   Hemoglobin Hb                                                                     23222517   1.80E-09    135367
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR with hypertension      22479191   8.00E-09    130600
  rs7805747   Chronic kidney disease                                                            20383146   8.60E-09    62237
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR males                  22479191   1.10E-08    130600
  rs7805747   Hematocrit Hct                                                                    23222517   3.92E-08    135367
  rs7805747   Red blood cell count RBC                                                          23222517   9.17E-08    135367
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR females                22479191   9.20E-08    130600
  rs7805747   Serum creatinine                                                                  20686651   2.20E-07    68439
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR with hypertension      20383146   2.60E-07    90075
  rs7805747   Serum cystatin c estimated glomerular filtration rate eGFR                        20383146   8.10E-07    90075
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR without hypertension   22479191   8.80E-07    130600
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR age 65                 22479191   1.10E-06    130600
  rs7805747   log(eGFR cystatin C)                                                              26831199   3.00E-06    32299
  rs7805747   Serum creatinine estimated glomerular filtration rate eGFR no hypertension        20383146   4.60E-06    90075
  rs7805747   SBP                                                                               27618447   6.35E-06    192763
  rs7805747   Cystatin C in serum                                                               20383146   1.80E-05    90075
  rs7805747   Serum cystatin c estimated glomerular filtration rate eGFR                        22479191   1.82E-05    130600
  rs7805747   Serum urate                                                                       23263486   3.91E-05    94744
  rs7805747   Chronic kidney disease severe                                                     22479191   1.00E-04    130600
  rs7805747   Breast cancer                                                                     23555315   0.00043     14905
  rs7805747   log(eGFR cystatin C)                                                              20383146   0.00045     20957
  rs7805747   Pulse pressure                                                                    27618447   0.0006478   192763
  rs7805747   Gout                                                                              23263486   0.0007558   69374
  rs7805747   Transmission distortion                                                           22377632   0.0009417   4728
  rs7805747   HbA1C                                                                             20858683   0.001555    46368
  rs7805747   Hypertension                                                                      27618447   0.003366    183273
  rs7805747   Plasma Beta 2 microglobulin levels                                                23417110   0.0065      6728
  rs7805747   Extraversion                                                                      26362575   0.006933    63030
  rs7805747   Height SDS for females aged 10 years                                              23449627   0.008512    6967
                                                                                                                       

eGFR, estimated glomerular filtration rate; SDS, standard deviation scores.

Functional Analysis of rs7805747 Using PhenoScanner in eQTL
-----------------------------------------------------------

Using PhenoScanner in eQTL option, we identified 23 significant associations between rs7805747 and gene expression with *P* \< 0.01. These findings show that rs7805747 is significantly associated with gene expression in multiple human tissues including brain, cells transformed fibroblasts, colon sigmoid, colon transverse, heart left ventricle, liver, lung, skin, small intestine terminal ileum, stomach, and whole blood, as described in Table [3](#T3){ref-type="table"}. These regulated genes include GIMAP1, GIMAP5, AGAP3, KCNH2, TMEM176B, TMEM176A, FASTK, WDR86, NOS3, WDR86-AS1, XRCC2, YBX1P4, SLC4A2, TMUB1, and PRKAG2. Importantly, rs7805747 could significantly regulate PRKAG2 expression in blood with *P* = 3.81E-03 and 8.15E-04.

###### 

Significant association between rs7805747 and the gene expression with *P* ≤ 0.01.

  SNP         PMID       Source     Tissue                                  Gene        Samples   Effect allele   Beta        SE        *P*-value
  ----------- ---------- ---------- --------------------------------------- ----------- --------- --------------- ----------- --------- -----------
  rs7805747   25954001   GTEx       Brain anterior cingulate cortex ba24    GIMAP1      72        A               --0.474     0.1675    6.68E-03
  rs7805747   25954001   GTEx       Brain caudate basal ganglia             GIMAP5      100       A                 0.3208    0.07913   1.18E-04
  rs7805747   25954001   GTEx       Brain cerebellar hemisphere             AGAP3       89        A               --0.2971    0.07884   3.50E-04
  rs7805747   25954001   GTEx       Brain cerebellum                        KCNH2       103       A                 0.2766    0.07274   2.76E-04
  rs7805747   25954001   GTEx       Brain cerebellum                        TMEM176B    103       A                 0.2503    0.08545   4.41E-03
  rs7805747   25954001   GTEx       Brain cortex                            TMEM176A    96        A                 0.2284    0.06774   1.19E-03
  rs7805747   25954001   GTEx       Brain cortex                            TMEM176B    96        A                 0.196     0.06142   2.08E-03
  rs7805747   25954001   GTEx       Brain nucleus accumbens basal ganglia   TMEM176B    93        A                 0.2308    0.0691    1.34E-03
  rs7805747   25954001   GTEx       Brain nucleus accumbens basal ganglia   FASTK       93        A               --0.1828    0.06627   7.37E-03
  rs7805747   25954001   GTEx       Brain putamen basal ganglia             GIMAP5      82        A                 0.256     0.0781    1.75E-03
  rs7805747   25954001   GTEx       Cells transformed fibroblasts           GIMAP5      272       A               --0.2152    0.07521   4.60E-03
  rs7805747   25954001   GTEx       Colon sigmoid                           WDR86       124       A                 0.1876    0.06838   7.19E-03
  rs7805747   25954001   GTEx       Colon transverse                        NOS3        169       A               --0.202     0.07399   7.20E-03
  rs7805747   25954001   GTEx       Colon transverse                        NA          169       A               --0.2624    0.09677   7.59E-03
  rs7805747   25954001   GTEx       Heart left ventricle                    WDR86-AS1   190       A                 0.277     0.1039    8.50E-03
  rs7805747   25954001   GTEx       Liver                                   XRCC2       97        A               --0.3458    0.1297    9.42E-03
  rs7805747   25954001   GTEx       Lung                                    YBX1P4      278       A                 0.2894    0.08621   9.19E-04
  rs7805747   25954001   GTEx       Skin not sun exposed suprapubic         FASTK       196       A               --0.1002    0.03668   7.01E-03
  rs7805747   25954001   GTEx       Small intestine terminal ileum          SLC4A2      77        A                 0.3245    0.08101   1.87E-04
  rs7805747   25954001   GTEx       Stomach                                 TMUB1       170       A                 0.1734    0.05787   3.26E-03
  rs7805747   25954001   GTEx       Whole blood                             PRKAG2      338       A               --0.145     0.04971   3.81E-03
  rs7805747   22941192   MuTHER     Skin                                    XRCC2       667       A                 0.09756   0.03317   3.30E-03
  rs7805747   24013639   Westra H   Peripheral blood                        PRKAG2      5311      NA                NA        NA        8.15E-04
                                                                                                                                        

Beta is the regression coefficient based on A allele, which means that A allele regulates increased (Beta \> 0) and reduced (Beta \< 0) expression of nearby genes.

Functional Analysis of rs7805747 Using PhenoScanner in Metabolites
------------------------------------------------------------------

Using PhenoScanner in metabolites option, we identified significant association between rs7805747 and 17 metabolites with *P* \< 0.01. These metabolites included Creatinine, Indolelactate, Phenol sulfate, Pseudouridine, Propionylcarnitine, C-glycosyltryptophan, Kynurenine, Myo-inositol, 3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF), 1-palmitoylglycerophosphoethanolamine, Phenyllactate (PLA), Erythronate, N-acetylthreonine, Citrulline, 3-methoxytyrosine, Urate, 2-methylbutyroylcarnitine, as described in Table [4](#T4){ref-type="table"}.

###### 

Significant association between rs7805747 and metabolites with *P* ≤ 0.01.

  SNP         Trait                                                  PMID       Effect allele   Beta      SE        *P*-value   Samples
  ----------- ------------------------------------------------------ ---------- --------------- --------- --------- ----------- ---------
  rs7805747   Creatinine                                             27005778   A               0.06017   0.01126   9.76E-08    24806
  rs7805747   Indolelactate                                          24816252   A               0.0131    0.0028    3.77E-06    6939
  rs7805747   Phenol sulfate                                         24816252   A               0.0202    0.0056    3.23E-04    7361
  rs7805747   Pseudouridine                                          24816252   A               0.0065    0.0018    4.24E-04    7336
  rs7805747   Propionylcarnitine                                     24816252   A               0.0093    0.0028    8.46E-04    7364
  rs7805747   C-glycosyltryptophan                                   24816252   A               0.0057    0.0018    1.89E-03    7338
  rs7805747   Kynurenine                                             24816252   A               0.008     0.0027    2.58E-03    7368
  rs7805747   Myo-inositol                                           24816252   A               0.008     0.0027    2.62E-03    7354
  rs7805747   3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF)   24816252   A               0.0278    0.0093    2.71E-03    7363
  rs7805747   1-palmitoylglycerophosphoethanolamine                  24816252   A               0.0081    0.0028    4.48E-03    7317
  rs7805747   Phenyllactate (PLA)                                    24816252   A               0.0081    0.0029    4.87E-03    5702
  rs7805747   Erythronate                                            24816252   A               0.0054    0.0019    5.10E-03    7307
  rs7805747   N-acetylthreonine                                      24816252   A               0.0077    0.0028    6.05E-03    6502
  rs7805747   Citrulline                                             24816252   A               0.0051    0.0019    6.30E-03    7325
  rs7805747   3-methoxytyrosine                                      24816252   A               0.0077    0.0028    6.38E-03    5656
  rs7805747   Urate                                                  24816252   A               0.005     0.0018    6.56E-03    7371
  rs7805747   2-methylbutyroylcarnitine                              24816252   A               0.0076    0.0028    6.76E-03    7007
                                                                                                                                

Beta is the regression coefficient based on A allele, which means that A allele regulates increased (Beta \> 0) and reduced (Beta \< 0) metabolites.

Gene Expression Analysis of PRKAG2 in GTEx
------------------------------------------

Using the UCSC Genome Browser, the results showed that PRKAG2 had the highest median expression: 34.90 RPKM in Heart -- Atrial Appendage (Ensembl gene ID: ENSG00000106617.9, Genomic position: hg38 chr7:151556111-151877125). PRKAG2 had the total median expression 412.37 RPKM in all these 53 tissues. Figure [1](#F1){ref-type="fig"} provided more detailed information about the PRKAG2 gene expression in 53 tissues from GTEx RNA-Seq of 8555 samples (570 donors).

![PRKAG2 gene expression in 53 tissues from GTEx RNA-Seq of 8555 samples (570 donors) using UCSC Genome Browser.](fgene-09-00573-g001){#F1}

Case-Control Gene Expression Analysis of PRKAG2
-----------------------------------------------

There are three probes to evaluate the expression of PRKAG2 gene in the gene expression profiles in human CKD including A_24_P384779, A_23_P44366, and A_23_P314760. Each of these three probes represents different regions of PRKAG2 gene. These three probes may have the same or different transcript or isoforms, or extrons. The results showed that all these probes about the PRKAG2 gene is significantly dysregulated in CKD cases compared with control samples including A_24_P384779 \[*P* = 1.23E-07 and log2(fold change) = -2.07\], and A_23_P44366 \[*P* = 4.39E-03 and log2(fold change) = 0.74\], and A_23_P314760 \[*P* = 1.54E-02 and log2(fold change) = 0.62\]. In Table [3](#T3){ref-type="table"}, there are 15 unique genes regulated by rs7805747. In addition to PRKAG2, we also evaluated the expression of other 14 genes, as provided in Table [3](#T3){ref-type="table"}. The results showed that 4 of other 14 genes including TMUB1, AGAP3, XRCC2, and WDR86-AS1 also had different expression in CKD cases with *P* \< 0.01. Table [5](#T5){ref-type="table"} provided the detailed information about 23 probes of 15 genes including PRKAG2. Importantly, the different expression of PRKAG2, TMUB1, AGAP3, and XRCC2 had passed the multiple testing correction threshold 0.01/23 = 0.000435.

###### 

Gene expression analysis of 15 genes regulated by rs7805747 using CKD gene expression dataset.

  Probe ID       Gene        Moderated t-statistic   log2(fold change)   *P*-value
  -------------- ----------- ----------------------- ------------------- -----------
  A_24_P384779   PRKAG2      --5.955014              --2.0719216         1.23E-07
  A_23_P31195    TMUB1          4.8579817              0.9257494         8.08E-06
  A_24_P333364   AGAP3          4.7795743              1.1776645         1.08E-05
  A_23_P134584   XRCC2          4.0270549              1.5434301         1.53E-04
  A_24_P317622   AGAP3       --3.5418815             --1.5220408         7.50E-04
  A_32_P138396   WDR86-AS1     3.5246206               1.3570183         7.92E-04
  A_23_P44366    PRKAG2        2.9543448               0.7360169         4.39E-03
  A_32_P77343    XRCC2       --2.8724894             --1.3978382         5.53E-03
  A_23_P314760   PRKAG2        2.4911763               0.6188034         1.54E-02
  A_23_P427023   GIMAP1        2.4154446               0.6207405         1.86E-02
  A_32_P123479   WDR86         2.2539559               0.8931606         2.77E-02
  A_23_P70849    NOS3          1.8409091               0.4171176         7.03E-02
  A_23_P253389   SLC4A2      --1.7570194             --0.6506201         8.37E-02
  A_23_P31188    GIMAP1        1.6700716               0.3545223         9.98E-02
  A_23_P252082   TMEM176A      1.6570106               0.6562679         1.02E-01
  A_23_P502930   FASTK         1.6067909               0.3109551         1.13E-01
  A_23_P42588    GIMAP5      --1.2244375             --0.337937          2.25E-01
  A_23_P377882   KCNH2       --1.1399471             --0.3027131         2.59E-01
  A_24_P354998   TMUB1         0.9443127               0.2498472         3.49E-01
  A_23_P168403   KCNH2       --0.9265106             --0.4312405         3.58E-01
  A_23_P157007   TMEM176B    --0.3719722             --0.1521275         7.11E-01
  A_23_P111452   AGAP3         0.3314008               0.1213519         7.41E-01
  A_23_P215140   FASTK         0.0048177               0.0008936         9.96E-01
                                                                         

Discussion
==========

It is reported that PRKAG2 could encode the gamma2-subunit isoform of 5′-AMP-activated protein kinase (AMPK) ([@B1]; [@B3]; [@B10]; [@B29]; [@B54]; [@B66]; [@B17], [@B18]). AMPK is a metabolic enzyme, which plays important roles in regulating of energy metabolism in response to cellular stress. AMPK has been identified to be a regulator of metabolism, survival, and fibrosis, by a recent integrative analysis of PRKAG2 cardiomyopathy iPS and microtissue models ([@B17]). In addition, mutations in PRKAG2 have been identified to be associated with hypertrophic cardiomyopathy ([@B64]).

Over the past decade, GWAS have considerably improved our understanding of the genetic basis of kidney function and disease ([@B63]). A SNP rs7805747 identified by CKD GWAS lies upstream of PRKAG2. Here, we performed a comprehensively functional analysis of this variant using multiple bioinformatics databases including RegulomeDB ([@B4]), HaploReg (version 4.1) ([@B60]), and PhenoScanner (version 1.1) ([@B53]). Using RegulomeDB, rs7805747 is predicted to affect HNF4A binding or DNase peak. Using RegulomeDB, the predicted score is 5, which suggested that rs7805747 is likely to affect binding (TF binding) or DNase peak. The predicted binding protein is HNF4A (chr7:151407767-151408030 by ChIP-seq in Caco2 cell type). In addition, rs7805747 was predicated to locate in enhancer histone marks (Liver, Fetal Intestine Large, Right Ventricle, Duodenum Mucosa, and Fetal Intestine Small). Using HaploReg (version 4.1), we identified rs7805747 to be associated with enhancer histone marks, DNase hypersensitivity, and motifs changed. In HaploReg (version 4.1), rs7805747 was also predicated to locate in enhancer histone marks (Liver, Duodenum Mucosa, Fetal Intestine Large, Fetal Intestine Small, and Right Ventricle tissues). Hence, the findings in HaploReg (version 4.1) were consistent with RegulomeDB.

Using PhenoScanner in GWAS option, we showed that rs7805747 is not only associated with CKD, but also is significantly associated with other diseases or phenotypes including Hemoglobin Hb, Hematocrit Hct, Red blood cell count RBC, SBP, Breast cancer, Gout, Hypertension, and Extraversion.

Using PhenoScanner in eQTL option, rs7805747 is identified to be significantly associated with gene expression in multiple human tissues and multiple genes including PRKAG2. Previous study has reported rs7805747 to be associated with serum creatinine and CKD ([@B7]). Using PhenoScanner in metabolites option, rs7805747 is identified to be significantly associated with not only the serum creatinine, but also with other 16 metabolites, as described in Table [4](#T4){ref-type="table"}.

The gene expression analysis of PRKAG2 using 53 tissues from GTEx RNA-Seq of 8555 samples (570 donors) in GTEx showed that PRKAG2 had the highest median expression in Heart -- Atrial Appendage. Using the gene expression profiles in human CKD, we further identified different expression of PRKAG2 gene in CKD cases compared with control samples. All these findings indicate that rs7805747 is associated with CKD risk, PRKAG2 gene expression, and 17 metabolites. Meanwhile, gene expression analysis further showed that CKD cases had different expression of PRKAG2 gene. In summary, our findings provide new insight into the underlying susceptibility of PRKAG2 gene to CKD.
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